
Rocket Pharma (RCKT) Stock Forecast & Price Target
Rocket Pharma (RCKT) Analyst Ratings
Bulls say
Rocket Pharmaceuticals is viewed positively because its Danon disease program now has clearer pivotal success criteria, and the available Phase I and early Phase II data show durable biologic activity with all six evaluable Phase I patients meeting responder criteria at 12 months and five of six remaining transplant-free at 58 months. The company also improved its financial flexibility by securing up to $150 million from Hercules Capital, including $35 million drawn at closing, which extends its runway into 3Q28 from 2Q28 and can be lengthened further by additional tranches. Fundamentally, the stock’s appeal is supported by a large underdiagnosed market of roughly 10,000 to 11,000 U.S. patients, plus more than $1 billion in potential peak revenue in the initial indication and over $2 billion with broader Danon expansion.
Bears say
Rocket Pharmaceuticals is viewed cautiously because it remains an early commercial-stage company with one approved product that is not yet generating revenue, while the majority of its pipeline is still clinical stage and exposed to regulatory and manufacturing setbacks. The outlook is further pressured by continuing cash burn, a runway into 3Q28 that may not extend through launch, and an expectation that additional Hercules draws or equity financing will be needed, potentially on dilutive or restrictive terms. On top of this, the RP-A501 clinical hold, the possibility of longer and more capital-intensive pivotal trials, and intense competition heighten execution risk and could delay commercialization or weaken future pricing power.
This aggregate rating is based on analysts' research of Rocket Pharma and is not a guaranteed prediction by Public.com or investment advice.
Rocket Pharma (RCKT) Analyst Forecast & Price Prediction
Start investing in Rocket Pharma (RCKT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Rocket Pharma (RCKT) Forecast
Rocket Pharma (RCKT) Analyst Forecast & Price Prediction
Start investing in Rocket Pharma (RCKT)
Order type
Buy in
Order amount
Est. shares
0 shares